CB2 receptors as new therapeutic targets for liver diseases

被引：83

作者：

Lotersztajn, S. ^{[1
,2
,3
]}

Teixeira-Clerc, F. ^{[1
,2
]}

Julien, B. ^{[1
,2
]}

Deveaux, V. ^{[1
,2
]}

Ichigotani, Y. ^{[1
,2
]}

Manin, S. ^{[1
,2
]}

Tran-Van-Nhieu, J. ^{[1
,2
,4
]}

Karsak, M. ^{[5
]}

Zimmer, A. ^{[5
]}

Mallat, A. ^{[1
,2
,3
]}

机构：

[1] Hop Henri Mondor, INSERM, U 841, Inst Mondor Rech Biomed, F-94010 Creteil, France

[2] Univ Paris 12, Creteil, France

[3] Grp Hosp Henri Mondor Albert Chenevier, AP HP, Serv Hepatol & Gastroenterol, Creteil, France

[4] Grp Hosp Henri Mondor Albert Chenevier, AP HP, Dept Pathol, Creteil, France

[5] Univ Bonn, Inst Mol Psychiat, D-5300 Bonn, Germany

来源：

BRITISH JOURNAL OF PHARMACOLOGY | 2008年 / 153卷 / 02期

关键词：

cannabinoid receptors; liver fibrosis; cirrhosis; ischaemia/reperfusion injury; liver diseases;

D O I：

10.1038/sj.bjp.0707511

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Cannabinoid type-1 (CB1) and type-2 (CB2) receptors belong to the family of G protein-coupled receptors and mediate biological effects of phyto-derived and endogenous cannabinoids. Whereas functions of CB1 receptor have been extensively studied, the CB2 receptor has emerged over the last few years as a critical player in regulation of inflammation, pain, atherosclerosis and osteoporosis. Therefore, although still at a preclinical stage, the development of selective CB2 molecules has gained of interest as new targets in drug discovery. Recent data have unravelled a key role of CB2 receptors during chronic and acute liver injury, including fibrogenesis associated to chronic liver diseases, ischaemia-reperfusion-induced liver injury, and hepatic encephalopathy associated to acute liver failure. This review summarizes the latest advances on the recently identified role of CB2 receptors in the pathophysiology of liver diseases.

引用

页码：286 / 289

页数：4

共 50 条

[1] CB2 and GPR55 Receptors as Therapeutic Targets for Systemic Immune Dysregulation
Zhou, Juan
Burkoyskiy, Ian
Yang, Hyewon
Sardinha, Joel
Lehmann, Christian
[J]. FRONTIERS IN PHARMACOLOGY, 2016, 7
[2] Cannabinoid CB2 Receptors in Neurodegenerative Proteinopathies: New Insights and Therapeutic Potential
Vuic, Barbara
Milos, Tina
Tudor, Lucija
Konjevod, Marcela
Perkovic, Matea Nikolac
Jembrek, Maja Jazvinscak
Erjavec, Gordana Nedic
Strac, Dubravka Svob
[J]. BIOMEDICINES, 2022, 10 (12)
[3] CANNABINOID CB2 RECEPTORS STIMULATE LIVER REGENERATION
Belot, M. -P
Teixeira-Clerc, F.
Manin, S.
Deveaux, V.
Van Nhieu, J. tran
Zimmer, A.
Mallat, A.
Lotersztajn, S.
[J]. JOURNAL OF HEPATOLOGY, 2009, 50 : S44 - S45
[4] CANNABINOID CB2 RECEPTORS PROMOTE LIVER REGENERATION
Teixeira-Clerc, Fatima
Belot, Marie-Pierre
Manin, Sylvie
Deveaux, Vanessa
Van Nhieu, Jeanne Tran
Zimmer, Andreas
Tordjmann, Thierry
Mallat, Arione
Lotersztajn, Sophie
[J]. HEPATOLOGY, 2008, 48 (04) : 435A - 435A
[5] CB2 cannabinoid receptors:: new vistas
Mackie, K.
Ross, R. A.
[J]. BRITISH JOURNAL OF PHARMACOLOGY, 2008, 153 (02) : 177 - 178
[6] New Insights and Potential Therapeutic Targeting of CB2 Cannabinoid Receptors in CNS Disorders
Kibret, Berhanu Geresu
Ishiguro, Hiroki
Horiuchi, Yasue
Onaivi, Emmanuel S.
[J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (02)
[7] CB2 receptors in reproduction
Maccarrone, M.
[J]. BRITISH JOURNAL OF PHARMACOLOGY, 2008, 153 (02) : 189 - 198
[8] Are CB2 Receptors a New Target for Schizophrenia Treatment?
Cortez, Isadora L.
Rodrigues da Silva, Naielly
Guimaraes, Francisco S.
Gomes, Felipe V.
[J]. FRONTIERS IN PSYCHIATRY, 2020, 11
[9] Cannabinoid Receptors as Therapeutic Targets in the Management of Liver Diseases
Mallat, Ariane
Lotersztajn, Sophie
[J]. DRUG NEWS & PERSPECTIVES, 2008, 21 (07) : 363 - 368
[10] Nuclear receptors as therapeutic targets in cholestatic liver diseases
Zollner, Gernot
Trauner, Michael
[J]. BRITISH JOURNAL OF PHARMACOLOGY, 2009, 156 (01) : 7 - 27

← 1 2 3 4 5 →